November 2016
Dermatology
Peer Reviewed

Sign in to continue reading this article

Not registered? Create an account for free to read full articles on www.cliniciansbrief.com.

To access full articles on www.cliniciansbrief.com, please sign in below.

Busy? Sign in Faster. Sign into www.cliniciansbrief.com with your social media account.

Dermatomyositis is an uncommon condition in dogs that predominantly affects the skin and, to a lesser extent, striated muscle.1 The exact cause is unknown, but an immune-mediated pathogenesis resulting in an ischemic dermatopathy is suspected.2 Dermatomyositis is predominantly seen in collies and Shetland sheepdogs, in which a familial predisposition is present. Other breeds may be affected, but a similar familial relationship has not been shown.

Clinical Signs

Clinical signs are variable in dogs and range from mild with spontaneous resolution to severe and debilitating. Cutaneous lesions usually appear before 6 months of age and occur on the face (periocular region, perioral region, muzzle), ears, distal extremities, and tail.2 Lesions are initially characterized by erythema, alopecia, scaling, and crusting and may progress to cicatricial alopecia. When clinical signs of myositis are present, they correlate to the severity of skin disease and manifest as difficulties with prehension of food, atrophy of masticatory and distal limb musculature, gait abnormalities, or regurgitation secondary to megaesophagus.3

Diagnosis

Diagnosis is based on signalment, recognition of typical changes, and ruling out other differentials; it is confirmed via histopathology. Muscle biopsy and electromyography aid in the diagnosis of myositis but are not routinely performed. Differential diagnoses include demodicosis, pyoderma, dermatophytosis, allergic dermatitis with secondary infections, other ischemic vasculopathies, and discoid lupus erythematosus.

Treatment

General recommendations include minimizing ultraviolet exposure and restricting activities that traumatize the skin, as both may exacerbate lesions. Daily supplementation with fatty acids and vitamin E (200-600 units PO q12h) may be beneficial in mild cases.3

In recurrent moderate-to-severe disease, therapy with pentoxifylline (15-25 mg/kg PO q8-12h) is commonly implemented and has historically been the drug of choice for this condition.3,4 In cases in which these recommendations do not control clinical signs, combination therapy with additional immunomodulatory agents (eg, tetracycline derivatives, niacinamide, glucocorticoids, cyclosporine, topical tacrolimus) should be pursued. Periodic flares should be expected and can be treated with short tapering courses of systemic glucocorticoids.3

Prognosis

Prognosis is highly variable and depends on disease severity as well as the ability to control signs while minimizing adverse events secondary to pharmaceutical intervention. Regardless of disease severity, affected dogs should not be bred.

References and author information Show
References
  1. Shelton GD. From dog to man: the broad spectrum of inflammatory myopathies. Neuromuscul Disord. 2007;17 (9-10):663-670.
  2. Miller WH, Griffin CE, Campbell KL. Familial canine dermatomyositis. In: Miller WH, Griffin CE, Campbell KL, eds. Muller and Kirk’s Small Animal Dermatology. 7th ed. St Louis, MO: Elsevier Mosby; 2013:585-587.
  3. Morris DO. Ischemic dermatopathies. Vet Clin North Am Small Anim Pract. 2013;43(1):99-111.
  4. Marsella R, Nicklin CF, Munson JW, Roberts SM. Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. Am J Vet Res. 2000;61(6):631-637.
Author

Darren Berger

DVM, DACVD Iowa State University

Darren Berger, DVM, DACVD, is assistant professor of dermatology at Iowa State University. Dr. Berger’s research interests include clinical pharmacology, dermatomycoses, and clinical management of canine atopic dermatitis and equine hypersensitivity disorders. After earning his DVM from Iowa State University, he completed a dermatology residency with Dermatology for Animals in Gilbert, Arizona.

Material from Clinician’s Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Up Next